株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

自家細胞療法の世界市場:2020年~2024年

Global Autologous Cell Therapy Market 2020-2024

発行 TechNavio (Infiniti Research Ltd.) 商品コード 513918
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.69円で換算しております。
自家細胞療法の世界市場:2020年~2024年 Global Autologous Cell Therapy Market 2020-2024
出版日: 2020年03月17日 ページ情報: 英文 120 Pages
概要

世界の自家細胞療法市場は、2020年から2024年の予測期間中に22%のCAGRで成長し、19億7,000万米ドルの規模に達する見込みです。心臓および変性疾患治療のための有効な薬の需要の増加が主な市場成長要因となっています。また、従来の臓器移植の限界によって、更に市場成長が促進される見通しです。

当レポートでは、世界の自家細胞療法市場について調査分析し、市場規模および成長率、市場動向、市場促進要因、課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模:2019年
  • 市場の見通し:2019-2024年の予測

ファイブフォース分析

他別市場セグメンテーション

  • 市場セグメンテーション
  • 治療法別比較:市場規模と予測2019-2024
  • 自家幹細胞療法
  • 自家細胞免疫療法
  • 治療法別市場機会

顧客情勢

  • 概要

地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模と予測2019-2024
  • 北米
  • 欧州
  • アジア太平洋地域
  • 南米
  • 中東・アフリカ地域
  • 主要国
  • 地域の市場機会

成長要因、課題、および動向

  • 市場成長要因
  • 数量的成長要因-需要主導型成長
  • 数量的成長要因-供給主導型成長
  • 数量的成長要因-外部要因
  • 数量的成長要因-隣接市場での需要シフト
  • 価格上昇要因-インフレ
  • 価格上昇要因-低価格ユニットから高価格ユニットへの移行
  • 市場の課題
  • 市場動向

ベンダー情勢

  • 概要
  • 情勢の革新
  • ベンダー分析

対象ベンダー

  • ベンダーの市場ポジショニング
  • Bayer AG
  • Brainstorm Cell Therapeutics Inc.
  • 第一三共
  • 富士フィルムホールディングス
  • Holostem Terapie Avanzate Srl
  • Osiris Therapeutics Inc.
  • 武田薬品工業
  • Teva Pharmaceutical Industries Ltd.
  • 住友化学
  • Vericel Corp.

付録

目次
Product Code: IRTNTR41330

Technavio has been monitoring the global autologous cell therapy market 2020-2024 and it is poised to grow by USD 1.97 bn during 2020-2024, progressing at a CAGR of 22% during the forecast period. Our reports on global autologous cell therapy market 2020-2024 provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing demand for effective drugs for cardiac and degenerative disorders. In addition, limitations in traditional organ transplantations fueling demand for stem cell therapies is anticipated to boost the growth of the global autologous cell therapy market 2020-2024 as well.

Market Segmentation

Technavio's ‘ global autologous cell therapy market 2020-2024 ’ is segmented as below:

Therapy:

  • Autologous Stem Cell Therapy
  • Autologus Cellular Immunotherapies

Application:

  • Oncology
  • Musculoskeletal Disorders
  • Dermatology

Geographic segmentation

  • North America
  • APAC
  • Europe
  • South America
  • MEA

Key Trends for global autologous cell therapy market 2020-2024 growth

This study identifies limitations in traditional organ transplantations fueling demand for stem cell therapies as the prime reasons driving the global autologous cell therapy market 2020-2024 growth during the next few years.

Prominent vendors in global autologous cell therapy market 2020-2024

We provide a detailed analysis of around 25 vendors operating in the global autologous cell therapy market 2020-2024, including some of the vendors such as Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., FUJIFILM Holdings Corp., Holostem Terapie Avanzate Srl, Osiris Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sumitomo Chemical Co. Ltd. and Vericel Corp. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Other 1

  • Market segments
  • Comparison by Other1 placement
  • Autologous stem cell therapy - Market size and forecast 2019-2024
  • Autologous cellular immunotherapies - Market size and forecast 2019-2024
  • Market opportunity by Other1

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • South America - Market size and forecast 2019-2024
  • MEA - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher-priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption
  • Vendor Analysis

Vendors covered

  • Market positioning of vendors
  • Bayer AG
  • Brainstorm Cell Therapeutics Inc.
  • Daiichi Sankyo Co. Ltd.
  • FUJIFILM Holdings Corp.
  • Holostem Terapie Avanzate Srl
  • Osiris Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sumitomo Chemical Co. Ltd.
  • Vericel Corp.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 5
  • 5.Key Finding 6
  • 6.Key Finding 7
  • 7.Key Finding 8
  • 8.Market in focus
  • 10.Parent market
  • 13.Market characteristics
  • 15.Offerings of vendors included in the market definition
  • 17.Market segments
  • 22.Global - Market size and forecast 2019 - 2024 ($ million)
  • 23.Global market: Year-over-year growth 2019 - 2024 (%)
  • 24.Five forces analysis 2019 & 2024
  • 26.Bargaining power of buyers
  • 27.Bargaining power of suppliers
  • 28.Threat of new entrants
  • 29.Threat of substitutes
  • 30.Threat of rivalry
  • 32.Market condition - Five forces 2019
  • 33.Other1 placement - Market share 2019-2024 (%)
  • 34.Comparison by Other1 placement
  • 35.Autologous stem cell therapy - Market size and forecast 2019-2024 ($ million)
  • 36.Autologous stem cell therapy - Year-over-year growth 2019-2024 (%)
  • 37.Autologous cellular immunotherapies - Market size and forecast 2019-2024 ($ million)
  • 38.Autologous cellular immunotherapies - Year-over-year growth 2019-2024 (%)
  • 39. Market opportunity by Other1
  • 40.Customer landscape
  • 41.Market share by geography 2019-2024 (%)
  • 42.Geographic comparison
  • 44.North America - Market size and forecast 2019-2024 ($ million)
  • 45.North America - Year-over-year growth 2019-2024 (%)
  • 47.Europe - Market size and forecast 2019-2024 ($ million)
  • 48.Europe - Year-over-year growth 2019-2024 (%)
  • 50.APAC - Market size and forecast 2019-2024 ($ million)
  • 51.APAC - Year-over-year growth 2019-2024 (%)
  • 53.South America - Market size and forecast 2019-2024 ($ million)
  • 54.South America - Year-over-year growth 2019-2024 (%)
  • 56.MEA - Market size and forecast 2019-2024 ($ million)
  • 57.MEA - Year-over-year growth 2019-2024 (%)
  • 58.Key leading countries
  • 59.Market opportunity by geography ($ million)
  • 60.Impact of drivers and challenges
  • 61.Vendor landscape
  • 63.Landscape disruption
  • 65.Industry risks
  • 67.Vendors covered
  • 69.Market positioning of vendors
  • 71.Bayer AG - Overview
  • 72.Bayer AG - Business segments
  • 73.Bayer AG - Key offerings
  • 74.Bayer AG - Key customers
  • 75.Bayer AG - Segment focus
  • 77.Brainstorm Cell Therapeutics Inc. - Overview
  • 78.Brainstorm Cell Therapeutics Inc. - Product and service
  • 79.Brainstorm Cell Therapeutics Inc. - Key offerings
  • 80.Brainstorm Cell Therapeutics Inc. - Key customers
  • 81.Brainstorm Cell Therapeutics Inc. - Segment focus
  • 83.Daiichi Sankyo Co. Ltd. - Overview
  • 84.Daiichi Sankyo Co. Ltd. - Business segments
  • 85.Daiichi Sankyo Co. Ltd. - Key offerings
  • 86.Daiichi Sankyo Co. Ltd. - Key customers
  • 87.Daiichi Sankyo Co. Ltd. - Segment focus
  • 89.FUJIFILM Holdings Corp. - Overview
  • 90.FUJIFILM Holdings Corp. - Business segments
  • 91.FUJIFILM Holdings Corp. - Key offerings
  • 92.FUJIFILM Holdings Corp. - Key customers
  • 93.FUJIFILM Holdings Corp. - Segment focus
  • 95.Holostem Terapie Avanzate Srl - Overview
  • 96.Holostem Terapie Avanzate Srl - Product and service
  • 97.Holostem Terapie Avanzate Srl - Key offerings
  • 98.Holostem Terapie Avanzate Srl - Key customers
  • 99.Holostem Terapie Avanzate Srl - Segment focus
  • 101.Osiris Therapeutics Inc. - Overview
  • 102.Osiris Therapeutics Inc. - Product and service
  • 103.Osiris Therapeutics Inc. - Key offerings
  • 104.Osiris Therapeutics Inc. - Key customers
  • 105.Osiris Therapeutics Inc. - Segment focus
  • 107.Takeda Pharmaceutical Co. Ltd. - Overview
  • 108.Takeda Pharmaceutical Co. Ltd. - Product and service
  • 109.Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 110.Takeda Pharmaceutical Co. Ltd. - Key customers
  • 111.Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 113.Teva Pharmaceutical Industries Ltd. - Overview
  • 114.Teva Pharmaceutical Industries Ltd. - Business segments
  • 115.Teva Pharmaceutical Industries Ltd. - Key offerings
  • 116.Teva Pharmaceutical Industries Ltd. - Key customers
  • 117.Teva Pharmaceutical Industries Ltd. - Segment focus
  • 119.Sumitomo Chemical Co. Ltd. - Overview
  • 120.Sumitomo Chemical Co. Ltd. - Business segments
  • 121.Sumitomo Chemical Co. Ltd. - Key offerings
  • 122.Sumitomo Chemical Co. Ltd. - Key customers
  • 123.Sumitomo Chemical Co. Ltd. - Segment focus
  • 125.Vericel Corp. - Overview
  • 126.Vericel Corp. - Product and service
  • 127.Vericel Corp. - Key offerings
  • 128.Vericel Corp. - Key customers
  • 129.Vericel Corp. - Segment focus
  • 131.Currency conversion rates for US$
  • 132.Research Methodology
  • 133.Validation techniques employed for market sizing
  • 134.Information sources
  • 135. List of abbreviations